✦ LIBER ✦

Efficacy, safety, and tolerability in patients switched to PEG (40 kDa) IFN α-2a (PEGASYS®) after discontinuation from interferon alfa-2b plus ribavirin (REBETRON™) combination therapy for chronic hepatitis C

✍ Scribed by Perrillo, Robert P.; Rothstein, Kenneth D.; Alam, Imtiaz; Thuluvath, Paul J.; Palmer, Melissa; Pockros, Paul J.; Cantwell, Susan; Pappas, Stephen C.

Book ID: 124137002
Publisher: Elsevier Science
Year: 2001
Tongue: English
Weight: 180 KB
Volume: 120
Category: Article
ISSN: 0016-5085
DOI: 10.1016/S0016-5085(08)82819-3

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Efficacy, quality of life, safety, and t

Efficacy, quality of life, safety, and tolerability in patients with chronic hepatitis C treated with PEG (40 kDa) IFN α-2a (PEGASYS®) or standard interferon Alfa-2b/ribavirin (REBETRON™) combination therapy

✍ Kenneth D. Rothstein; Robert P. Perrillo; Joanne Imperial; Imtiaz Alam; Melissa 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 366 KB

Tolerability of 40 kDa peginterferon alf

Tolerability of 40 kDa peginterferon alfa-2A (PEGASYS®) versus standard interferon alfa-2B/ribavirin combination therapy (IFN/RBV) in patients with chronic hepatitis C (CHC): Robert P Perrillo, Ochsner Clinic, New Orleans, LA; Kenneth D Rothstein, Albert Einstein Medical Ctr, Philadelphia, PA; Paul J Thuluvath, Johns Hopkins Hospital, Baltimore, MD; Imtiaz Alam, Center for Clinical Research, Austin, TX; Joanne Imperial, Stanford Medical Center, Palo Alto, CA; Bradley Doerschuk, Lucy Wynohradnyk, S. Chris Pappas, Roche Laboratories Inc, Nutley, NJ

📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 222 KB

Analyses of 40 kDa peginterferon alfa-2A

Analyses of 40 kDa peginterferon alfa-2A (Pegasys®) in combination with ribavirin, mycophenolate mofetil, amantadine, or amantadine plus ribavirin in patients that relapsed or did not respond to rebetron™ therapy: a report of two randomized, multicenter, efficacy and safety studies: Nezam Afdhal, Beth Israel Deaconess Medical Ctr, Boston, MA; Steven Flamm, Northwestern Memorial Hospital, Chicago, IL; Joanne C Imperial, Stanford University School of Medicine, Palo Alto, CA; Peter F Malet, University of Texas Southwestern Medical Center, Dallas, TX; Myron Tong, Hungtington Hospital Liver Center, Pasadena, CA; Steven K Herrine, Thomas Jefferson University Hospital, Philadelphia, PA; Robert Brown Jr., Columbia Presbyterian Medical Center, New York, NY; Stephen Esposito, Hepatobiliary Associates of New York, Bayside, NY; David E Bernstein, North Shore University Hospital, Manhasset, NY; Jennifer L Campagna, Roche Laboratories Inc, Nutley, NJ

📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 235 KB